Antifungal Agents - Cresemba (isavuconazonium), Vfend. Prior Authorization Program Summary

Size: px
Start display at page:

Download "Antifungal Agents - Cresemba (isavuconazonium), Vfend. Prior Authorization Program Summary"

Transcription

1 Antifungal Agents - Cresemba (isavuconazonium), Noxafil (posaconazole), Vfend (voriconazole) Prior Authorization Program Summary FDA APPROVED INDICATIONS DOSAGE 1,2,14 Drug FDA Indication(s) Dosing Cresemba (isavuconazonium) capsules, injection Noxafil (posaconazole) oral suspension Noxafil (posaconazole) delayed-release tablet, injection Vfend (voriconazole) tablets a, oral suspension a, injection a a available as generic Treatment of invasive aspergillosis and invasive mucormycosis Prophylaxis against invasive aspergillosis or candida in patients at high risk Treatment of oropharyngeal candidiasis refractory to itraconazole or fluconazole Prophylaxis of invasive Aspergillus and Candida infections in patients who are at high risk of developing these infections due to being severely immunocompromised Treatment of invasive aspergillosis, candidemia, esophageal candidiasis, serious fungal infections caused by Scedosporium and Fusarium Loading Dose mg every 8 hours for 6 doses. Maintenance Dose mg once daily starting hours after the last loading dose. Prophylaxis against invasive aspergillosis or candida Suspension mg 3 times daily Tablets, Injection mg twice daily first day, then 300 mg once a day Oropharyngeal candidiasis, non refractory mg twice on day one then 100 mg daily Refractory oropharyngeal candidiasis mg twice daily Loading dose mg IV/delayedrelease tablet twice a day on the first day. Maintenance dose mg IV/delayed release tablet once a day thereafter. Duration of therapy is based on recovery from neutropenia or immunosuppression. 200 mg every 12 hours for all indications CLINICAL RATIONALE Isavuconazonium is not included in guidelines as it was approved after guidelines publication. Esophageal candidiasis and candidemia 3,7 Infectious Diseases Society of America (IDSA) guidelines recommend oral fluconazole as the first line therapy for candidemia in nonneutropenic patients and for esophageal candidiasis. 3 Fluconazole is also recommended for prophylaxis against esophageal candidiasis in at risk patients. 3 For patients with fluconazole-refractory disease, guidelines recommend itraconazole or voriconazole. 7 Up to 80% of patients with fluconazole refractory esophageal candidiasis will respond to itraconazole. Voriconazole has demonstrated effectiveness for both mucosal and Choice_PS_Cresemba_Noxafil_Vfend_PA_ProgSum_0117_r0517 Page 1 of 8

2 invasive candidiasis. Its clinical use has been primarily for step-down oral therapy in patients with infection due to C. krusei and fluconazole-resistant, voriconazole-susceptible C. glabrata. 3 Aspergillus and rare fungal infections 4,7,11-13 IDSA guidelines recommend posaconazole for prophylaxis against aspergillus in hematopoietic stem cell transplant (HSCT) recipients with graft versus host disease (GVHD) at high risk, acute myeloid leukemia (AML), or myelodysplastic syndrome at high risk. IDSA guidelines recommend voriconazole for treatment of invasive aspergillosis in most patients, with posaconazole a possible second line therapy. IDSA has not published guidelines for treatment of the rare fungal infections scedosporiosis or zygomycosis (mucormycosis). Voriconazole demonstrated superiority compared to amphotericin B in the treatment of invasive aspergillosis. Infectious diseases guidelines indicate voriconazole as a first line agent for the treatment of invasive aspergillosis, fusariosis, and scedosporiosis, but currently do not list it as an alternative for zygomycosis. Posaconazole is an alternative for the treatment of invasive aspergillosis, scedosporiosis, and zygomycosis. Many of these fungal infections are lifethreatening with high mortality rates. Isavuconazonium for the treatment of aspergillus or other filamentous fungi was studied in a randomized, double-blind, non-inferiority active controlled trial which evaluated the safety and efficacy of isavuconazonium (N=258) versus voriconazole (N=258) in patients. All-cause mortality through Day 42 in the overall population (ITT) was 18.6% in the isavuconazonium treatment group and 20.2% in the voriconazole treatment group for an adjusted treatment difference of -1.0% with 95% confidence interval of -8.0% to 5.9%. Similar results were seen in patients with proven or probable invasive aspergillosis confirmed by serology, culture or histology. Overall success at End-of-Treatment (EOT) was assessed by a blinded, independent Data Review Committee (DRC) using pre-specified clinical, mycological, and radiological criteria. In the subgroup of patients with proven or probable invasive aspergillosis confirmed by serology, culture or histology, overall success at EOT was seen in 35% of isavuconazoniumtreated patients compared to 38.9% of voriconazole-treated patients. Invasive mucormycosis is a serious and rare disease in which active controlled clinical trials are not feasible. 19 The only antifungal drug approved for this indication is amphotericin B, which can be associated with several adverse events and also has limitations with regard to use in patients with renal impairment. 19 Epidemiological reports have found a high mortality rate in patients with mucormycosis who did not receive treatment Isavuconazonium was studied in the treatment of mucormycosis open-label non-comparative trial, evaluated the safety and efficacy of a subset of patients with invasive mucormycosis. All cause mortality through day 42 for pimary treatment, treatment refractory to, or patients intolerant to other antifungal therapy were 7 (33%), 5 (46%), and 2 (40%) respectively. The overall success rate at endof-treatment for primary treatment, treatment refractory to, or patients intolerant of other antifungal therapy were 6 (32%), 4 (36%), and 1 (20%) respectively. 14 Isavuconazonium is contraindicated in those with hypersensitivity to isavuconazonium; coadministration with strong CYP3A4 inhibitors, such as ketoconazole or high-dose ritonavir; coadministration with strong CYP3A4 inducers, such as rifampin, carbamazepine, St. John s wort, or long acting barbiturates; use in patients with familial short QT syndrome. 14 The ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis strongly recommend diagnosis of mucormycosis using direct microscopy, histopathology, and culture are strongly recommended. Imaging is strongly recommended to determine the extent of the disease. The use of galactomannan detection is moderately supported for the diagnosis of invasive mucormycosis. For adults and children, surgical debridement in addition to immediate first-lineantifungal treatment with liposomal or lipidcomplex amphotericin B is strongly recommended. For salvage treatment, we strongly recommend posaconazole. Reversal of predisposing condition is strongly recommended. Choice_PS_Cresemba_Noxafil_Vfend_PA_ProgSum_0117_r0517 Page 2 of 8

3 Continued treatment is strongly recommended until a complete response is demonstrated on imaging and permanent reversal of predisposing factors. 15 Blastomycosis and histoplasmosis 5-7 Itraconazole is the recommended therapy for the treatment of chronic cavity pulmonary histoplasmosis. Other forms of histoplasmosis are generally treated with amphotericin B. IDSA guidelines recommend itraconazole as the first line oral agent for the treatment of mild to moderate blastomycosis. Itraconazole is also recommended in patients as a step down from amphotericin B for more severe cases of blastomycosis. Fluconazole and voriconazole are considered alternatives for the treatment of blastomycosis. Solid Organ Transplant Patients Solid organ transplant patients, especially those with liver, pancreas, lung, or heart-lung transplants, may be at risk for fungal infections. The most common infecting fungal organisms are Candida and Aspergillus. 8 Since prophylactic drug therapy may be associated with toxicity and resistance, guidelines recommend that it be targeted to patients at highest risk of morbidity and mortality. 8,9 Factors that may place a patient at high risk of a fungal infection include: primary allograft dysfunction, nonfunction, or retransplantation; prolonged operative duration; high intra-operative blood product requirement and bleeding complications; pretransplant immunosuppression; pre-operative CMV infection; prolonged ICU requirement or mechanical ventilation; prolonged use of broad-spectrum antibacterial therapy; renal failure; fungal colonization, unrecognized recipient fungal infection, or donor fungemia or positive fungal cultures; gastrointestinal translocation or transplantation of a colonic segment. 8,9 The 2004 guidelines from the American Society of Transplantation recommend amphotericin B, itraconazole and/or fluconazole, depending on the specific situation. 8 Due to development of increased resistance to itraconazole and fluconazole, posaconazole and voriconazole have been studied as prophylactic therapy in solid organ transplant patients and may be recommended by some clinicians. 7,9 Hematopoietic Stem Cell Transplant (HSCT) Recipients Patients undergoing hematopoietic stem cell transplants are at an increased risk of infection with infection being the primary cause of death in 8% of autologous HSCT patients and 17%- 20% of allogeneic HCT recipients. 10 Risk factors for fungal infection in this population includes mucositis, neutropenia, and GVHD. 10 Additionally, allogeneic transplant recipients are at a significantly higher risk for fungal infection than those receiving autologous marrow stem cells. Guidelines recommend fluconazole as the drug of choice for the prophylaxis of invasive candidiasis though there is increasing resistance to fluconazole. 10 The IDSA guidelines for treatment of Aspergillosis, published in 2008, recommend posaconazole for antifungal prophylaxis in HSCT recipients with GVHD at high risk of infection. Itraconazole may be an alternative but its utility is limited by tolerability issues. 4 Voriconazole has demonstrated efficacy in secondary prophylaxis of invasive aspergillosis. 4,10 For additional clinical information see the Prime Therapeutics Formulary Chapter 1.9A: Antifungal Agents, Imidazole and Triazole Agents. REFERENCES 1. Vfend prescribing information. Pfizer. Februrary Noxafil prescribing information. Schering. November Clin Infect Dis 2016; accessed in April 2016 at: 4. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008;46: Choice_PS_Cresemba_Noxafil_Vfend_PA_ProgSum_0117_r0517 Page 3 of 8

4 5. Chapman SW, Dismukes WE, Proia LA, et al. Clinical practice guidelines for the management of blastomycosis: 2008 update by the Infectious Disease Society of America. Clin Infec Dis. 2009;48: Wheat LJ, Freifeld AG, Lkeiman MB, et al. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis. 2007;45: Antifungal Drugs. Medical Letter Treatment Guidelines. 2009;7(88): Fungal infections. Am J Transplant. 2004;4(Suppl 10): Gabardi S, Kubiak DW, Chandraker AK, Tullius SG. Invasive fungal infections and antifungal therapies in solid organ transplant recipients. Transplant International. 2007;20(12): Tomblyn M, Chiller T, Einele H et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant. 2009;15(10): Crum-Cianflone NF. Mucomycosis. Available at: Accessed September Vazquez JA. Zycomycosis. Available at: Accessed September Centers for Disease Control and Prevention (CDC). Mucomycosis (Zycomycosis). Available at: Accessed September Cresemba prescribing information. Astellas Pharma US, Inc. April ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mcormycosis Clin Microbiol Infect 2014; 20 (suppl.3): Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005;41(5): Skiada A, Pagano L, Groll A, et al. Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and Clin Microbiol Infect 2011; 17(12): Chamilos G, Lewis RE, Kontoyiannis DP. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis 2008;47(4): Center for Drug Evaluation and Research. Application number: Orig1s000/207501Orig1s000. FDA Medical review. Accessed in May 2015 at: 000MedR.pdf Choice_PS_Cresemba_Noxafil_Vfend_PA_ProgSum_0117_r0517 Page 4 of 8

5 Cresemba (isavuconazonium), Noxafil (posaconazole), and Vfend (voriconazole) Prior Authorization OBJECTIVE The intent of the Cresemba (isavuconazonium), Noxafil (posaconazole), and Vfend (voriconazole) Prior Authorization (PA) program is to ensure appropriate selection of patients for treatment according to product labeling and/or clinical studies and/or clinical practice guidelines. The PA process allows for approval for labeled indications and may require trial and failure of another antifungal agent when Cresemba, Noxafil, and Vfend are indicated in clinical practice guidelines as an alternative agent for the diagnosis, unless the patient has documented intolerance, FDA labeled contraindication, or hypersensitivity to the recommended initial treatment choice. Cresemba, Noxafil, or Vfend may also be evaluated for a nonlabeled indication if recommended in clinical practice guidelines or if the prescriber submits documentation in support of the requested therapeutic use. TARGET DRUGS Cresemba (isavuconazonium) Noxafil (posaconazole) Vfend (voriconazole) a a available as generic; included as target in PA program PRI AUTHIZATION CRITERIA F APPROVAL Initial Evaluation: Cresemba (isavuconazonium) will be approved when BOTH of the following are met: 1. The patient does NOT have any FDA labeled contraindication(s) to the requested agent 2. ONE of the following: a. The patient has a diagnosis of invasive aspergillosis b. The patient has a diagnosis of invasive mucormycosis c. The prescriber has submitted documentation supporting use of the requested agent for the intended diagnosis for this patient which has been reviewed and approved by the Clinical Review pharmacist Length of approval: 6 months Noxafil (posaconazole) will be approved when BOTH of the following are met: 1. The patient does NOT have any FDA labeled contraindication(s) to the requested agent 2. ONE of the following: a. The patient has a diagnosis of oropharyngeal candidiasis patient has tried fluconazole or an alternative antifungal agent or patient has documented intolerance, FDA labeled contraindication, or hypersensitivity to fluconazole or an alternative antifungal agent b. The patient is severely immunocompromised, such as a hematopoietic stem cell transplant [HSCT] recipient; or a patient with a hematologic malignancy with prolonged neutropenia from chemotherapy; or is a high-risk solid organ (lung, heart-lung, liver, pancreas, small bowel) transplant patient the requested agent is prescribed for prophylaxis of invasive Aspergillus or Candida c. The patient has an infection caused by Scedosporium or Zygomycetes Choice_PS_Cresemba_Noxafil_Vfend_PA_ProgSum_0117_r0517 Page 5 of 8

6 d. The patient has a diagnosis of invasive Aspergillus patient has tried an alternative antifungal agent or patient has documented intolerance, FDA labeled contraindication, or hypersensitivity to an alternative antifungal agent e. The prescriber has submitted documentation supporting use of the requested agent for the intended diagnosis for this patient which has been reviewed and approved by the Clinical Review pharmacist Length of approval: one month for oropharyngeal, 6 months for all other indications Vfend (voriconazole) will be approved when BOTH of the following are met: 1. The patient does NOT have any FDA labeled contraindication(s) to the requested agent 2. ONE of the following: a. The patient has a diagnosis of invasive Aspergillus, Scedosporium apiospermum, or Fusarium b. The patient has a diagnosis of esophageal candidiasis or candidemia in nonneutropenic patient patient has tried fluconazole or an alternative antifungal agent or patient has documented intolerance, FDA labeled contraindication, or hypersensitivity to an alternative antifungal agent c. The patient has a diagnosis of blastomycosis patient has tried itraconazole patient has documented intolerance, FDA labeled contraindication, or hypersensitivity to itraconazole d. The patient is severely immunocompromised, such as a hematopoietic stem cell transplant [HSCT] recipient; or a patient with a hematologic malignancy with prolonged neutropenia from chemotherapy; or is a high-risk solid organ (lung, heart-lung, liver, pancreas, small bowel) transplant patient e. The prescriber has submitted documentation supporting use of the requested agent for the intended diagnosis for this patient which has been reviewed and approved by the Clinical Review pharmacist Length of approval: one month for oropharyngeal and esophageal candidiasis, 6 months for all other indications Renewal Evaluation Cresemba (isavuconazonium) will be approved when ALL of the following are met: 1. The patient has been previously approved for the requested agent through the Prime Therapeutics Prior Authorization process 2. The patient does NOT have any FDA labeled contraindication(s) to the requested agent 3. ONE of the following: a. The patient has a diagnosis of invasive aspergillosis and the patient has continued indicators of active disease (e.g. continued radiologic findings, positive cultures, positive serum galactomannan assay) b. The patient has a diagnosis of invasive mucormycosis and the patient has continued indicators of active disease (e.g. continued radiologic findings, direct Choice_PS_Cresemba_Noxafil_Vfend_PA_ProgSum_0117_r0517 Page 6 of 8

7 microscopy findings, histopathology findings, positive cultures, positive serum galactomannan assay) c. The prescriber has submitted documentation supporting continued use of the requested agent for the intended diagnosis for this patient which has been reviewed and approved by the Clinical Review pharmacist Length of approval: 6 months Noxafil (posaconazole) will be approved when ALL of the following are met: 1. The patient has been previously approved for the requested agent through the Prime Therapeutics Prior Authorization process 2. The patient does NOT have any FDA labeled contraindication(s) to the requested agent 3. ONE of the following: a. The requested agent is being prescribed for prophylaxis of invasive Aspergillus or Candida and the patient continues to be severely immunocompromised as indicated by: neutropenia, ongoing graft versus host disease, and/or long term use of high dose corticosteroids (> 1 mg/kg/day of prednisone or equivalent) b. The patient has a diagnosis of invasive Aspergillus or has an infection caused by Scedosporium, or Zygomycetes and the patient has continued indicators of active disease (e.g. continued radiologic findings, positive cultures, positive serum galactomannan assay for Aspergillus) c. The prescriber has submitted documentation supporting continued use of the requested agent for the intended diagnosis for this patient which has been reviewed and approved by the Clinical Review pharmacist -For patients with a diagnosis of oropharyngeal candidiasis see Initial Evaluation criteria Length of approval: 6 months Vfend (voriconazole) will be approved when ALL of the following are met: 1. The patient has been previously approved for the requested agent through the Prime Therapeutics Prior Authorization process 2. The patient does NOT have any FDA labeled contraindication(s) to the requested agent 3. ONE of the following: a. The patient has a diagnosis of invasive Aspergillus, Scedosporium apiospermum, Fusarium, esophageal candidiasis, candidemia in nonneutropenic patient or blastomycosis and the patient has continued indicators of active disease (e.g. continued radiologic findings, positive cultures, positive serum galactomannan assay for Aspergillus) b. The requested agent is being prescribed for prophylaxis and the patient continues to be severely immunocompromised as indicated by: neutropenia, ongoing graft versus host disease, and/or long term use of high dose corticosteroids (> 1 mg/kg/day of prednisone or equivalent) c. The prescriber has submitted documentation supporting continued use of the requested agent for the intended diagnosis for this patient which has been reviewed and approved by the Clinical Review pharmacist Choice_PS_Cresemba_Noxafil_Vfend_PA_ProgSum_0117_r0517 Page 7 of 8

8 Length of approval: one month for esophageal candidiasis 6 months for all other indications Choice_PS_Cresemba_Noxafil_Vfend_PA_ProgSum_0117_r0517 Page 8 of 8

Cigna Drug and Biologic Coverage Policy

Cigna Drug and Biologic Coverage Policy Cigna Drug and Biologic Coverage Policy Subject Voriconazole Effective Date... 3/15/2018 Next Review Date... 3/15/2019 Coverage Policy Number... 4004 Table of Contents Coverage Policy... 1 General Background...

More information

Voriconazole October 2015 Risk Management Plan. Voriconazole

Voriconazole October 2015 Risk Management Plan. Voriconazole Voriconazole October 2015 VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Invasive aspergillosis (IA) is the most devastating of Aspergillus related diseases, targeting severely

More information

Prophylaxis versus Diagnostics-driven approaches to treatment of Invasive fungal diseases. Y.L. Kwong Department of Medicine University of Hong Kong

Prophylaxis versus Diagnostics-driven approaches to treatment of Invasive fungal diseases. Y.L. Kwong Department of Medicine University of Hong Kong Prophylaxis versus Diagnostics-driven approaches to treatment of Invasive fungal diseases Y.L. Kwong Department of Medicine University of Hong Kong Pathogenic yeast Candida Cryptococcus Trichosporon Pathogenic

More information

EMERGING FUNGAL INFECTIONS IN IMMUNOCOMPROMISED PATIENTS

EMERGING FUNGAL INFECTIONS IN IMMUNOCOMPROMISED PATIENTS EMERGING FUNGAL INFECTIONS IN IMMUNOCOMPROMISED PATIENTS DR LOW CHIAN YONG MBBS, MRCP(UK), MMed(Int Med), FAMS Consultant, Dept of Infectious Diseases, SGH Introduction The incidence of invasive fungal

More information

Antifungals in Invasive Fungal Infections: Antifungals in neutropenic patients

Antifungals in Invasive Fungal Infections: Antifungals in neutropenic patients BVIKM-SBIMC La Hulpe, 6 November 2008 Antifungals in Invasive Fungal Infections: Antifungals in neutropenic patients Johan Maertens, MD Acute Leukemia and SCT Unit University Hospital Gasthuisberg Catholic

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Noxafil) Reference Number: AZ.CP.PHAR.30 Effective Date: 11.16.16 Last Review Date: 09.12.18 Line of Business: Arizona Medicaid Revision Log See Important Reminder at the end of this

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Vfend) Reference Number: AZ.CP.PHAR.39 Effective Date: 11.16.16 Last Review Date: 09.11.18 Line of Business: Arizona Medicaid Revision Log See Important Reminder at the end of this policy

More information

mycoses Prospective antifungal therapy (PATH) alliance â : focus on mucormycosis Summary Introduction

mycoses Prospective antifungal therapy (PATH) alliance â : focus on mucormycosis Summary Introduction mycoses Diagnosis,Therapy and Prophylaxis of Fungal Diseases Original article Prospective antifungal therapy (PATH) alliance â : focus on mucormycosis Dimitrios P. Kontoyiannis, 1 Nkechi Azie, 2 Billy

More information

Form 2046 R3.0: Fungal Infection Pre-HSCT Date

Form 2046 R3.0: Fungal Infection Pre-HSCT Date Key Fields Sequence Number: Date Received: - - CIBMTR Center Number: CIBMTR Recipient ID: Today's Date: - - Date of HSCT for which this form is being completed: - - HSCT type: (check all that apply) Autologous

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: itraconazole (Sporanox) Reference Number: HIM.PA.36 Effective Date: 05/16 Last Review Date: Line of Business: Health Insurance Marketplace Coding Implications Revision Log See Important

More information

Nationwide survey of treatment for pediatric patients with invasive fungal infections in Japan

Nationwide survey of treatment for pediatric patients with invasive fungal infections in Japan J Infect Chemother (2013) 19:946 950 DOI 10.1007/s10156-013-0624-7 ORIGINAL ARTICLE Nationwide survey of treatment for pediatric patients with invasive fungal infections in Japan Masaaki Mori Received:

More information

London New Drugs Group APC/DTC Briefing

London New Drugs Group APC/DTC Briefing London New Drugs Group APC/DTC Briefing Posaconazole for invasive fungal infections Contents Background 2 Dosing Information 3 Clinical evidence for treatment of infections 3 Clinical evidence for prophyactic

More information

Therapy of Hematologic Malignancies Period at high risk of IFI

Therapy of Hematologic Malignancies Period at high risk of IFI Therapy of Hematologic Malignancies Period at high risk of IFI Neutrophils (/mm 3 ) 5 Chemotherapy Conditioning Regimen HSCT Engraftment GVHD + Immunosuppressive Treatment Cutaneous and mucositis : - Direct

More information

Condition First line Alternative Comments Candidemia Nonneutropenic adults

Condition First line Alternative Comments Candidemia Nonneutropenic adults Recommendations for the treatment of candidiasis. Clinical Practice Guidelines for the Management of Candidiasis: 2009 Update by the Infectious Diseases Society of America. Condition First line Alternative

More information

Primary prophylaxis of invasive fungal infection in patients with haematological diseases

Primary prophylaxis of invasive fungal infection in patients with haematological diseases Primary prophylaxis of invasive fungal infection in patients with haematological diseases Tunis, May 24 2012 Important questions for antifungal prophylaxis Who are the patients at risk? Which is the risk:

More information

Micafungin, a new Echinocandin: Pediatric Development

Micafungin, a new Echinocandin: Pediatric Development Micafungin, a new Echinocandin: Pediatric Development Andreas H. Groll, M.D. Infectious Disease Research Program Center for Bone Marrow Transplantation and Department of Pediatric Hematology/Oncology University

More information

Antifungal prophylaxis in haematology patients: the role of voriconazole

Antifungal prophylaxis in haematology patients: the role of voriconazole REVIEW 10.1111/j.1469-0691.2012.03772.x Antifungal prophylaxis in haematology patients: the role of voriconazole Y. Hicheri 1, G. Cook 2 and C. Cordonnier 1 1) Service d Hématologie Clinique, Assistance

More information

Difficulties with Fungal Infections in Acute Myelogenous Leukemia Patients: Immune Enhancement Strategies

Difficulties with Fungal Infections in Acute Myelogenous Leukemia Patients: Immune Enhancement Strategies Difficulties with Fungal Infections in Acute Myelogenous Leukemia Patients: Immune Enhancement Strategies Amar Safdar The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA Key Words.

More information

Antifungals and current treatment guidelines in pediatrics and neonatology

Antifungals and current treatment guidelines in pediatrics and neonatology Dragana Janic Antifungals and current treatment guidelines in pediatrics and neonatology Dragana Janic. University Children`s Hospital, Belgrade, Serbia 10/10/17 Hotel Crowne Plaza, Belgrade, Serbia; www.dtfd.org

More information

PROGRESSI NELLA TERAPIA ANTIFUNGINA. A tribute to Piero Martino

PROGRESSI NELLA TERAPIA ANTIFUNGINA. A tribute to Piero Martino PROGRESSI NELLA TERAPIA ANTIFUNGINA A tribute to Piero Martino 1946-2007 ITALIAN ICONS IERI, OGGI, E DOMANI IERI, OGGI, E DOMANI IERI, OGGI, E DOMANI 1961 CAUSES OF DEATH IN PATIENTS WITH MALIGNANCIES

More information

Clinical Policy: Itraconazole (Onmel, Sporanox) Reference Number: ERX.NPA.25 Effective Date:

Clinical Policy: Itraconazole (Onmel, Sporanox) Reference Number: ERX.NPA.25 Effective Date: Clinical Policy: (Onmel, Sporanox) Reference Number: ERX.NPA.25 Effective Date: 06.01.15 Last Review Date: 05.18 Revision Log See Important Reminder at the end of this policy for important regulatory and

More information

MANAGEMENT OF HOSPITAL-ACQUIRED FUNGAL INFECTIONS

MANAGEMENT OF HOSPITAL-ACQUIRED FUNGAL INFECTIONS MANAGEMENT OF HOSPITAL-ACQUIRED FUNGAL INFECTIONS Paul D. Holtom, MD Associate Professor of Medicine and Orthopaedics USC Keck School of Medicine Numbers of Cases of Sepsis in the United States, According

More information

CURRENT AND NEWER ANTI-FUNGAL THERAPIES- MECHANISMS, INDICATIONS, LIMITATIONS AND PROBLEMS. Dr AMIT RAODEO DM SEMINAR

CURRENT AND NEWER ANTI-FUNGAL THERAPIES- MECHANISMS, INDICATIONS, LIMITATIONS AND PROBLEMS. Dr AMIT RAODEO DM SEMINAR CURRENT AND NEWER ANTI-FUNGAL THERAPIES- MECHANISMS, INDICATIONS, LIMITATIONS AND PROBLEMS Dr AMIT RAODEO DM SEMINAR Introduction The incidence of invasive fungal infections in critically ill intensive

More information

Prophylactic Strategies for Invasive Fungal Diseases in Hematological Stem Cell Transplantation: An Update

Prophylactic Strategies for Invasive Fungal Diseases in Hematological Stem Cell Transplantation: An Update DOI 10.6314/JIMT.201802_29(1).05 2018 29 38-45 Prophylactic Strategies for Invasive Fungal Diseases in Hematological Stem Cell Transplantation: An Update Alice Ying-Jung Wu 1, Hsiang-Kuang Tseng 1,2, and

More information

Rezafungin: A Novel Echinocandin. Taylor Sandison, MD MPH Chief Medical Officer ISHAM- Amsterdam July 2, 2018

Rezafungin: A Novel Echinocandin. Taylor Sandison, MD MPH Chief Medical Officer ISHAM- Amsterdam July 2, 2018 : A Novel Echinocandin Taylor Sandison, MD MPH Chief Medical Officer ISHAM- Amsterdam July 2, 2018 Disclosures Dr. Sandison is an employee of and stockholder in Cidara Therapeutics. Cidara Pipeline Program

More information

Itraconazole vs. fluconazole for antifungal prophylaxis in allogeneic stem-cell transplant patients D. J. Winston

Itraconazole vs. fluconazole for antifungal prophylaxis in allogeneic stem-cell transplant patients D. J. Winston REVIEW Itraconazole vs. fluconazole for antifungal prophylaxis in allogeneic stem-cell transplant patients D. J. Winston Division of Hematology-Oncology, Department of Medicine, UCLA Medical Center, Los

More information

Title: Author: Speciality / Division: Directorate:

Title: Author: Speciality / Division: Directorate: Antifungal guidelines for CANDIDIASIS INFECTIONS (Adults) Proven infection: Targeted antifungal therapy should be prescribed for: o Positive cultures from a sterile site with clinical or radiological abnormality

More information

Fungi GUIDE TO INFECTION CONTROL IN THE HOSPITAL CHAPTER NUMBER 53: Author Moi Lin Ling, MBBS, FRCPA, CPHQ, MBA

Fungi GUIDE TO INFECTION CONTROL IN THE HOSPITAL CHAPTER NUMBER 53: Author Moi Lin Ling, MBBS, FRCPA, CPHQ, MBA GUIDE TO INFECTION CONTROL IN THE HOSPITAL CHAPTER NUMBER 53: Fungi Author Moi Lin Ling, MBBS, FRCPA, CPHQ, MBA Chapter Editor Ziad A. Memish, MD, FRCPC, FACP Cover heading - Topic Outline Topic outline

More information

Isavuconazole. Lepak et al 2013 Antimicrob Agents Chemother 57: Lepak et al 2013 Antimicrob Agents Chemother 57:

Isavuconazole. Lepak et al 2013 Antimicrob Agents Chemother 57: Lepak et al 2013 Antimicrob Agents Chemother 57: Priv.-Doz. Dr. med. Maria J.G.T. Vehreschild Department I of Internal Medicine Clinical Trials Unit II Infectious Diseases Research Group Clinical Microbiome Isavuconazole 09.07.2017 Maria J.G.T. Vehreschild

More information

Use of Antifungal Drugs in the Year 2006"

Use of Antifungal Drugs in the Year 2006 Use of Antifungal Drugs in the Year 2006" Jose G. Montoya, MD Associate Professor of Medicine Associate Chief for Clinical Affairs Division of Infectious Diseases Stanford University School of Medicine

More information

EMA Pediatric Web Synopsis Protocol A November 2011 Final PFIZER INC.

EMA Pediatric Web Synopsis Protocol A November 2011 Final PFIZER INC. PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.

More information

ESCMID Online Lecture Library. by author

ESCMID Online Lecture Library. by author The antibacterial experience: indications for clinical use of antimicrobial combinations To prevent the emergence of resistant organisms (tuberculosis) To treat polymicrobial infections (abdominal complicated

More information

WHICH ANTIFUNGAL AGENT IS THE CHOICE FOR SUSPECTED FUNGAL INFECTIONS?

WHICH ANTIFUNGAL AGENT IS THE CHOICE FOR SUSPECTED FUNGAL INFECTIONS? WHICH ANTIFUNGAL AGENT IS THE CHOICE FOR SUSPECTED FUNGAL INFECTIONS? Assoc. Prof. Dr. Serkan SENER Acibadem University Medical School Department of Emergency Medicine, Istanbul Acibadem Ankara Hospital,

More information

How Can We Prevent Invasive Fungal Disease?

How Can We Prevent Invasive Fungal Disease? How Can We Prevent Invasive Fungal Disease? Chris Kibbler Professor of Medical Microbiology University College London And Royal Free Hospital, London, UK Invasive Aspergillosis 2 - Acquisition Preventive

More information

Case Studies in Fungal Infections and Antifungal Therapy

Case Studies in Fungal Infections and Antifungal Therapy Case Studies in Fungal Infections and Antifungal Therapy Wayne L. Gold MD, FRCPC Annual Meeting of the Canadian Society of Internal Medicine November 4, 2017 Disclosures No financial disclosures or industry

More information

Use of Antifungals in the Year 2008

Use of Antifungals in the Year 2008 Use of Antifungals in the Year 2008 Jose G. Montoya, MD Associate Professor of Medicine Associate Chief for Clinical Affairs Division of Infectious Diseases Stanford University School of Medicine Diagnosis

More information

What have we learned about systemic antifungals currently available on the market?

What have we learned about systemic antifungals currently available on the market? 2nd ECMM/CEMM Workshop Milano, September 25, 2010 What have we learned about systemic antifungals currently available on the market? Prof. Dr. Georg Maschmeyer Dept. of Hematology, Oncology & Palliative

More information

New Directions in Invasive Fungal Disease: Therapeutic Considerations

New Directions in Invasive Fungal Disease: Therapeutic Considerations New Directions in Invasive Fungal Disease: Therapeutic Considerations Coleman Rotstein, MD, FRCPC, FACP University of Toronto University Health Network Toronto, Ontario Disclosure Statement for Coleman

More information

Approach to the Transplant Patient. Amy Musiek, MD AAD Annual Meeting 2018

Approach to the Transplant Patient. Amy Musiek, MD AAD Annual Meeting 2018 Approach to the Transplant Patient Amy Musiek, MD AAD Annual Meeting 2018 Disclosures Actelion: speaker, advisory board, investigator Elorac: investigator Kyowa: investigator, advisory board Seattle genetics:

More information

Historically, amphotericin B deoxycholate

Historically, amphotericin B deoxycholate OUR CURRENT UNDERSTANDING OF THERAPIES FOR INVASIVE FUNGAL INFECTIONS * John R. Perfect, MD ABSTRACT This article provides an update on the current state of the art for treating invasive fungal infections,

More information

Invasive Fungal Infections in Solid Organ Transplant Recipients

Invasive Fungal Infections in Solid Organ Transplant Recipients Outlines Epidemiology Candidiasis Aspergillosis Invasive Fungal Infections in Solid Organ Transplant Recipients Hsin-Yun Sun, M.D. Division of Infectious Diseases Department of Internal Medicine National

More information

Challenges and controversies of Invasive fungal Infections

Challenges and controversies of Invasive fungal Infections Challenges and controversies of Invasive fungal Infections Mona Al-Dabbagh, MD, MHSc Assistant Professor of Pediatrics, COM-KSAU-HS Consultant Pediatric Infectious Diseases and Transplant Infectious Diseases

More information

Fungal Infection Pre-Infusion Data

Fungal Infection Pre-Infusion Data Fungal Infection Pre-Infusion Data Registry Use Only Sequence Number: Date Received: CIBMTR Center Number: Event date: / / CIBMTR Form 2046 revision 5 (page 1 of 5). Last Updated May, 2018. Infection Episode

More information

How Can We Tailor Antifungal Therapy?

How Can We Tailor Antifungal Therapy? How Can We Tailor Antifungal Therapy? Russell Lewis Infections Diseases Unit Department of Medical Sciences and Surgery S.Orsola Malpighi Hospital University of Bologna Most Common Infectious Diagnosis

More information

Improving Clinical Outcomes in Fungal Infection Control and Management

Improving Clinical Outcomes in Fungal Infection Control and Management Improving Clinical Outcomes in Fungal Infection Control and Management DISCLAIMER The information within this CME/CE activity is for continuing education purposes only, and is not intended to substitute

More information

Voriconazole 200 mg powder for solution for infusion 03 Jun version 3.0 PUBLIC SUMMARY OF THE RISK MANAGEMENT PLAN

Voriconazole 200 mg powder for solution for infusion 03 Jun version 3.0 PUBLIC SUMMARY OF THE RISK MANAGEMENT PLAN Voriconazole 200 mg powder for solution for infusion 03 Jun. 2015 version 3.0 PUBLIC SUMMARY OF THE RISK MANAGEMENT PLAN VI.2 Elements for a Public Summary VI.2.1 Overview of Disease Epidemiology Voriconazole

More information

Antifungal therapy guidelines

Antifungal therapy guidelines Background Invasive fungal infections (IFI) can cause significant morbidity and mortality among patients with haematological malignancies. There is good evidence for the use of antifungal prophylaxis in

More information

TOWARDS PRE-EMPTIVE? TRADITIONAL DIAGNOSIS. GALACTOMANNAN Sensitivity 61% Specificity 93% Neg Predict Value >95% β-d-glucan Neg Predict Value 100% PCR

TOWARDS PRE-EMPTIVE? TRADITIONAL DIAGNOSIS. GALACTOMANNAN Sensitivity 61% Specificity 93% Neg Predict Value >95% β-d-glucan Neg Predict Value 100% PCR TOWARDS PRE-EMPTIVE? GALACTOMANNAN Sensitivity 61% Specificity 93% Neg Predict Value >95% TRADITIONAL DIAGNOSIS β-d-glucan Neg Predict Value 100% PCR diagnostics FUNGAL BURDEN FIRST TEST POSITIVE FOR ASPERGILLOSIS

More information

PAGL Inclusion Approved at January 2017 PGC

PAGL Inclusion Approved at January 2017 PGC Guideline for the prophylaxis and treatment of fungal infections in Haematology patients 1. Introduction PAGL Inclusion Approved at January 2017 PGC Haematology, CHUGGS June 2016 This guideline sets out

More information

Amphotericin B lipid complex: treatment of invasive fungal infections in patients refractory to or intolerant of amphotericin B deoxycholate

Amphotericin B lipid complex: treatment of invasive fungal infections in patients refractory to or intolerant of amphotericin B deoxycholate REVIEW Amphotericin B lipid complex: treatment of invasive fungal infections in patients refractory to or intolerant of amphotericin B deoxycholate PH Chandrasekar Division of Infectious Diseases, Department

More information

We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors

We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,800 116,000 120M Open access books available International authors and editors Downloads Our

More information

ESCMID Online Lecture Library. by author. Salvage Therapy of Invasive Aspergillosis Refractory to Primary Treatment with Voriconazole

ESCMID Online Lecture Library. by author. Salvage Therapy of Invasive Aspergillosis Refractory to Primary Treatment with Voriconazole Salvage Therapy of Invasive Aspergillosis Refractory to Primary Treatment with Voriconazole J.A. Maertens, hematologist, MD, PhD University Hospital Gasthuisberg Leuven, Belgium Current guidelines: first-line

More information

ASPERGILLOSIS IN THE NON-NEUTROPENIC HOST

ASPERGILLOSIS IN THE NON-NEUTROPENIC HOST ASPERGILLOSIS IN THE NON-NEUTROPENIC HOST Dr J Garbino University Hospital Geneva ASPERGILLOSIS IN THE NON-NEUTROPENIC HOST INTRODUCTION SWISS ASPERGILLOSIS SURVEY IN THE NON-NEUTROPENIC HOST Introduction

More information

Aspergillosis in Pediatric Patients

Aspergillosis in Pediatric Patients Aspergillosis in Pediatric Patients Emmanuel Roilides, MD, PhD, FIDSA, FAAM 3rd Department of Pediatrics Aristotle University School of Medicine Thessaloniki, Greece 1 Transparency disclosures Independent

More information

Fungal infections in ICU. Tang Swee Fong Department of Paediatrics Universiti Kebangsaan Malaysia

Fungal infections in ICU. Tang Swee Fong Department of Paediatrics Universiti Kebangsaan Malaysia Fungal infections in ICU Tang Swee Fong Department of Paediatrics Universiti Kebangsaan Malaysia Epidemiology of invasive fungal infections - US +300% Martin GS, et al. N Engl J Med 2003;348:1546-1554

More information

Oliver A. Cornely. Department I for Internal Medicine Haematology / Oncology / Infectious Diseases / Intensive Care 2. Centre for Clinical Research

Oliver A. Cornely. Department I for Internal Medicine Haematology / Oncology / Infectious Diseases / Intensive Care 2. Centre for Clinical Research Management of Confirmed Aspergillosis Oliver A. Cornely 1 Department I for Internal Medicine Haematology / Oncology / Infectious Diseases / Intensive Care 2 Centre for Clinical Research University of Cologne

More information

TRANSPARENCY COMMITTEE OPINION. 8 November 2006

TRANSPARENCY COMMITTEE OPINION. 8 November 2006 The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 8 November 2006 VFEND 50 mg, film-coated tablets B/28 (CIP: 3592886) B/56 (CIP: 3592892) VFEND 200 mg, film-coated

More information

amphotericin B empiric therapy; preemptive therapy presumptive therapy Preemptive therapy Presumptive therapy ET targeted therapy ET

amphotericin B empiric therapy; preemptive therapy presumptive therapy Preemptive therapy Presumptive therapy ET targeted therapy ET 4 17 9 27 17 1 7 amphotericin B 34 empiric therapy; ET preemptive therapy presumptive therapy Preemptive therapy Presumptive therapy ET targeted therapy ET Key words: antifungal therapyempiric therapypreemptive

More information

Current options of antifungal therapy in invasive candidiasis

Current options of antifungal therapy in invasive candidiasis Current options of antifungal therapy in invasive candidiasis Saloua Ladeb Bone Marrow Transplant Center Tunis HAMMAMET 24 th April 2012 DEFINITION One or more positive results on blood culture for Candida

More information

anidulafungin 100mg powder and solvent for concentrate for solution for infusion (Ecalta ) No. (465/08) Pfizer Ltd

anidulafungin 100mg powder and solvent for concentrate for solution for infusion (Ecalta ) No. (465/08) Pfizer Ltd Scottish Medicines Consortium Re-Submission anidulafungin 100mg powder and solvent for concentrate for solution for infusion (Ecalta ) No. (465/08) Pfizer Ltd 10 October 2008 The Scottish Medicines Consortium

More information

MANAGEMENT OF PULMONARY MYCOSIS

MANAGEMENT OF PULMONARY MYCOSIS MANAGEMENT OF PULMONARY MYCOSIS Eva Van Braeckel, MD, PhD Dpt. of Respiratory Medicine UZ Gent PENTALFA KU Leuven 03.03.2016 MANAGEMENT OF PULMONARY MYCOSIS 1. Antifungals 1. Acute invasive pulmonary aspergillosis

More information

ADEQUATE ANTIFUNGAL USE FOR BLOODSTREAM INFECTIONS

ADEQUATE ANTIFUNGAL USE FOR BLOODSTREAM INFECTIONS ADEQUATE ANTIFUNGAL USE FOR BLOODSTREAM INFECTIONS COMMERCIAL RELATIONS DISCLOSURE 2500 9000 15000 Astellas Gilead Sciences Pfizer Inc Expert advice Speaker s bureau Speaker s bureau OUTLINE OF THE PRESENTATION

More information

9/7/2018. Faculty. Overcoming Challenges in the Management of Invasive Fungal Infections. Learning Objectives. Faculty Disclosure

9/7/2018. Faculty. Overcoming Challenges in the Management of Invasive Fungal Infections. Learning Objectives. Faculty Disclosure Faculty Overcoming Challenges in the Management of Invasive Fungal James S. Lewis II, PharmD, FIDSA ID Clinical Pharmacy Coordinator Oregon Health and Science University Departments of Pharmacy and Infectious

More information

Prophylaxis, Empirical, Pre-emptive Therapy of Aspergillosis in Hematological Patients: Which Strategy?

Prophylaxis, Empirical, Pre-emptive Therapy of Aspergillosis in Hematological Patients: Which Strategy? TIMM-4 18-21 October 2009 Athens, Greece Prophylaxis, Empirical, Pre-emptive Therapy of Aspergillosis in Hematological Patients: Which Strategy? www.ichs.org Georg Maschmeyer Dept. of Hematology, Oncology

More information

SCIENTIFIC DISCUSSION

SCIENTIFIC DISCUSSION London, 14 July 2004 Product name: Cancidas Procedure No. EMEA/H/C/379/II/17 SCIENTIFIC DISCUSSION 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 86 68

More information

Antifungal Update. Candida: In Vitro Antifungal Susceptibility Testing

Antifungal Update. Candida: In Vitro Antifungal Susceptibility Testing Antifungal Update B. Joseph Guglielmo, Pharm.D. Professor and Chair Department of Clinical Pharmacy School of Pharmacy University of California San Francisco The patient spikes a new fever and 3/3 blood

More information

Combination Antifungal Therapy for Invasive Aspergillosis

Combination Antifungal Therapy for Invasive Aspergillosis MAJOR ARTICLE Combination Antifungal Therapy for Invasive Aspergillosis Kieren A. Marr, 1,2 Michael Boeckh, 1,2 Rachel A. Carter, 1 Hyung Woo Kim, 1 and Lawrence Corey 1,2 1 Fred Hutchinson Cancer Research

More information

Supplementary appendix

Supplementary appendix Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Maertens JA, Raad II, Marr KA, et al. Isavuconazole

More information

ADVANCES AND CHALLENGES IN HEMATOLOGY. Invasive fungal disease management in febrile neutropenia

ADVANCES AND CHALLENGES IN HEMATOLOGY. Invasive fungal disease management in febrile neutropenia 16 th Annual Meeting of Saudi Society of Hematology 7 th Pan Arab Hematology Association Congress ADVANCES AND CHALLENGES IN HEMATOLOGY Invasive fungal disease management in febrile neutropenia J.A. Maertens,

More information

Management Strategies For Invasive Mycoses: An MD Anderson Perspective

Management Strategies For Invasive Mycoses: An MD Anderson Perspective Management Strategies For Invasive Mycoses: An MD Anderson Perspective Dimitrios P. Kontoyiannis, MD, ScD, FACP, FIDSA Professor of Medicine Director of Mycology Research Program M. D. Anderson Cancer

More information

Common Fungi. Catherine Diamond MD MPH

Common Fungi. Catherine Diamond MD MPH Common Fungi Catherine Diamond MD MPH Birth Month and Day & Last Four Digits of Your Cell Phone # BEFORE: http://tinyurl.com/kvfy3ts AFTER: http://tinyurl.com/lc4dzwr Clinically Common Fungi Yeast Mold

More information

Amphotericin B Lipid Complex (Abelcet ) 05/06

Amphotericin B Lipid Complex (Abelcet ) 05/06 Amphotericin B Lipid Complex (Abelcet ) Structure and Activity AMB : DMPC : DMPG lipid complex, 10:7:3 mol:mol ribbon-like lipid structures, 1.6-11 µm in diameter binds to ergosterol disturbance of cell

More information

Updated Guidelines for Management of Candidiasis. Vidya Sankar, DMD, MHS April 6, 2017

Updated Guidelines for Management of Candidiasis. Vidya Sankar, DMD, MHS April 6, 2017 Updated Guidelines for Management of Candidiasis Vidya Sankar, DMD, MHS April 6, 2017 Statement of Disclosure I have no actual or potential conflict of interest in relation to this presentation Outline

More information

Current Options in Antifungal Pharmacotherapy

Current Options in Antifungal Pharmacotherapy Current Options in Antifungal Pharmacotherapy John Mohr, Pharm.D., Melissa Johnson, Pharm.D., Travis Cooper, Pharm.D., James S. Lewis, II, Pharm.D., and Luis Ostrosky-Zeichner, M.D. Infections caused by

More information

Fungal Infection Post-Infusion Data

Fungal Infection Post-Infusion Data Fungal Infection Post-Infusion Data Registry Use Only Sequence Number: Date Received: CIBMTR Center Number: Event date: / / Visit: 100 day 6 months 1 year 2 years >2 years. Specify: CIBMTR Form 2146 revision

More information

When is failure failure?

When is failure failure? When is failure failure? Bart-Jan Kullberg, M.D. Radboud University Nijmegen The Netherlands The ICU patient with candidemia!! Female, 39 years old!! Multiple abdominal surgeries for Crohn's disease!!

More information

Top 5 papers in clinical mycology

Top 5 papers in clinical mycology Top 5 papers in clinical mycology Dirk Vogelaers Department of General Internal Medicine University Hospital Ghent Joint symposium BVIKM/BSIMC and SBMHA/BVMDM Influenza-associated aspergillosis in critically

More information

Antifungal Pharmacodynamics A Strategy to Optimize Efficacy

Antifungal Pharmacodynamics A Strategy to Optimize Efficacy Antifungal Pharmacodynamics A Strategy to Optimize Efficacy David Andes, MD Associate Professor, Department of Medicine Division of Infectious Diseases Medical Microbiology and Immunology University of

More information

Summary of the risk management plan (RMP) for Cresemba (isavuconazole)

Summary of the risk management plan (RMP) for Cresemba (isavuconazole) EMA/576866/2015 Summary of the risk management plan (RMP) for Cresemba (isavuconazole) This is a summary of the risk management plan (RMP) for Cresemba, which details the measures to be taken in order

More information

Invasive Pulmonary Aspergillosis in

Invasive Pulmonary Aspergillosis in Infection & Sepsis Symposium Porto, April 1-3, 2009 Invasive Pulmonary Aspergillosis in Non-Immunocompromised Patients Stijn BLOT, PhD General Internal Medicine & Infectious Diseases Ghent University Hospital,

More information

Antifungal Therapy in Leukemia Patients

Antifungal Therapy in Leukemia Patients Antifungal Therapy in Leukemia Patients UPDATE ECIL 4, 6 September 2011 Raoul Herbrecht, Ursula Flückiger, Bertrand Gachot, Patricia Ribaud, Anne Thiebaut, Catherine Cordonnier UPDATE ECIL 4, 2011 UPDATE

More information

Treatment and Prophylaxis

Treatment and Prophylaxis Treatment and Prophylaxis Andreas H. Groll, M.D. Infectious Disease Research Program Center for Bone Marrow Transplantation and Department of Pediatric Hematology/Oncology University Children s Hospital

More information

Fungi are eukaryotic With rigid cell walls composed largely of chitin rather than peptidoglycan (a characteristic component of most bacterial cell

Fungi are eukaryotic With rigid cell walls composed largely of chitin rather than peptidoglycan (a characteristic component of most bacterial cell Antifungal Drugs Fungal infections (Mycoses) Often chronic in nature. Mycotic infections may be superficial and involve only the skin (cutaneous mycoses extending into the epidermis) Others may penetrate

More information

Evidence-Based Approaches to the Safe and Effective Management of Invasive Fungal Infections. Presenter. Disclosures

Evidence-Based Approaches to the Safe and Effective Management of Invasive Fungal Infections. Presenter. Disclosures Evidence-Based Approaches to the Safe and Effective Management of Invasive Fungal Infections Presenter James S. Lewis II, PharmD, FIDSA ID Clinical Pharmacy Coordinator Oregon Health and Science University

More information

No Evidence As Yet. Georg Maschmeyer. Dept. of Hematology, Oncology & Palliative Care Klinikum Ernst von Bergmann Potsdam, Germany

No Evidence As Yet. Georg Maschmeyer. Dept. of Hematology, Oncology & Palliative Care Klinikum Ernst von Bergmann Potsdam, Germany Is Combined Antifungal Therapy More Efficient than Single Agent Therapy? No Evidence As Yet www.ichs.org Georg Maschmeyer Dept. of Hematology, Oncology & Palliative Care Klinikum Ernst von Bergmann Potsdam,

More information

Abstract. Introduction. Editor: M. Paul

Abstract. Introduction. Editor: M. Paul ORIGINAL ARTICLE MYCOLOGY Incidence of invasive fungal disease after unmanipulated haploidentical stem cell transplantation was significantly higher than that after HLA-matched sibling transplantation

More information

Diagnosis,Therapy and Prophylaxis of Fungal Diseases

Diagnosis,Therapy and Prophylaxis of Fungal Diseases mycoses Diagnosis,Therapy and Prophylaxis of Fungal Diseases Original article Epidemiology and sites of involvement of invasive fungal infections in patients with haematological malignancies: a 20-year

More information

Monitorization, Separation and Quantification of Antifungals used for Invasive Aspergillosis Treatment by High Performance Thin Layer Chromatography

Monitorization, Separation and Quantification of Antifungals used for Invasive Aspergillosis Treatment by High Performance Thin Layer Chromatography Monitorization, Separation and Quantification of Antifungals used for Invasive Aspergillosis Treatment by High Performance Thin Layer Chromatography M. P. Domingo, M. Vidal, J. Pardo, A. Rezusta, L. Roc,

More information

Department of Pediatric Hematology/Oncology, University Children s Hospital Tübingen, Hoppe-Seyler-Strß 1, Tübingen, Germany 2

Department of Pediatric Hematology/Oncology, University Children s Hospital Tübingen, Hoppe-Seyler-Strß 1, Tübingen, Germany 2 Case Reports in Transplantation Volume 2012, Article ID 672923, 4 pages doi:10.1155/2012/672923 Case Report Eradication of Pulmonary Aspergillosis in an Adolescent Patient Undergoing Three Allogeneic Stem

More information

Antifungal Update 2/22/12. Which is the most appropriate initial empirical therapy in a candidemic patient?

Antifungal Update 2/22/12. Which is the most appropriate initial empirical therapy in a candidemic patient? Antifungal Update B. Joseph Guglielmo, Pharm.D. Professor and Chair Department of Clinical Pharmacy School of Pharmacy University of California San Francisco 3/3 blood cultures are positive for an unidentified

More information

Invasive aspergillosis in pediatric patients

Invasive aspergillosis in pediatric patients Current Medical Research and Opinion ISSN: 0300-7995 (Print) 1473-4877 (Online) Journal homepage: http://www.tandfonline.com/loi/icmo20 Invasive aspergillosis in pediatric patients William J. Steinbach

More information

REVIEW. Servicio de Hematología, Unidad de Enfermedades Infecciosas and Servicio de Microbiología, Hospital Universitario La Fe, Valencia, Spain

REVIEW. Servicio de Hematología, Unidad de Enfermedades Infecciosas and Servicio de Microbiología, Hospital Universitario La Fe, Valencia, Spain REVIEW Epidemiology of invasive fungal infections due to Aspergillus spp. and Zygomycetes M. A. Sanz Alonso, I. Jarque Ramos, M. Salavert Lletí, J. Pemán Servicio de Hematología, Unidad de Enfermedades

More information

A CME/CE-CERTIFIED WEBCOURSE. Program Transcript

A CME/CE-CERTIFIED WEBCOURSE. Program Transcript A CME/CE-CERTIFIED WEBCOURSE Program Transcript Program Steering Committee/Faculty: ELIAS ANAISSIE, MD Medical Director, CTI Clinical Trial and Consulting Services Associate, Metropolitan Infectious Diseases

More information

Outline NEW DIAGNOSTIC TOOLS WHY? WHICH TESTS? WHEN TO USE THEM? Documented IFI

Outline NEW DIAGNOSTIC TOOLS WHY? WHICH TESTS? WHEN TO USE THEM? Documented IFI New Developments and Challenges in Diagnostics of Invasive Fungal Infections O. Marchetti, MD Infectious Diseases Service, Department of Medicine, CHUV and University of Lausanne, Switzerland Workshop

More information

Elements for a Public Summary. [Product Name] 40 mg/ml oral suspension. VI.2.1 Overview of disease epidemiology

Elements for a Public Summary. [Product Name] 40 mg/ml oral suspension. VI.2.1 Overview of disease epidemiology VI.2 Elements for a Public Summary [Product Name] 40 mg/ml oral suspension VI.2.1 Overview of disease epidemiology Fungi (yeasts) are small organisms that feed by breaking down tissue. In humans, fungi

More information

ECMM Excellence Centers Quality Audit

ECMM Excellence Centers Quality Audit ECMM Excellence Centers Quality Audit Person in charge: Department: Head of Department: Laboratory is accredited according to ISO 15189 (Medical Laboratories Requirements for quality and competence) Inspected

More information

Management of fungal infection

Management of fungal infection Management of fungal infection HKDU symposium 17 th May 2015 Speaker: Dr. Thomas Chan MBBS (Hons), MRCP, FHKCP, FHKAM Synopsis Infection caused by fungus mycoses Skin infection by fungus is common in general

More information

ESCMID Online Lecture Library. by author

ESCMID Online Lecture Library. by author How To Best Use Antifungal Agents Cornelia Lass-Flörl Division of Hygiene and Medical Microbiology Innsbruck Medical University ESCMID SUMMER SCHOOL 2012 Epidemiology Diagnosis Roadmap Antifungal drugs

More information

Micafungin and Candida spp. Rationale for the EUCAST clinical breakpoints. Version February 2013

Micafungin and Candida spp. Rationale for the EUCAST clinical breakpoints. Version February 2013 Micafungin and Candida spp. Rationale for the EUCAST clinical breakpoints. Version 1.0 5 February 2013 Foreword EUCAST The European Committee on Antimicrobial Susceptibility Testing (EUCAST) is organised

More information

HOW TO DEFINE RESPONSE IN ANTIFUNGAL CLINICAL TRIALS?

HOW TO DEFINE RESPONSE IN ANTIFUNGAL CLINICAL TRIALS? HOW TO DEFINE RESPONSE IN ANTIFUNGAL CLINICAL TRIALS? EORTC IFICG START Look for Help? MORTALITYASSOCIATED WITH INVASIVE ASPERGILLOSIS Lin et al. Clin Infect Dis 2001;32:358 100 % 50 n = 178 0 0 60 120

More information